{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T03:31:47Z","timestamp":1770348707874,"version":"3.49.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1053\/j.seminhematol.2009.02.003","type":"journal-article","created":{"date-parts":[[2009,4,22]],"date-time":"2009-04-22T04:17:47Z","timestamp":1240373867000},"page":"166-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib"],"prefix":"10.1053","volume":"46","author":[{"given":"Constantine S.","family":"Mitsiades","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teru","family":"Hideshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharminder","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas W.","family":"McMillin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Klippel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob P.","family":"Laubach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2009.02.003_bib1","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/anie.200390115","article-title":"Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora","volume":"42","author":"Feling","year":"2003","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib4","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib5","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib6","doi-asserted-by":"crossref","first-page":"10403","DOI":"10.1073\/pnas.96.18.10403","article-title":"Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity","volume":"96","author":"Meng","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib7","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib8","first-page":"687A","article-title":"Multicenter phase I studies to evaluate the safety, tolerability, and clinical response to intensive dosing with the proteasome inhibitor PR-171 in patients with relapsed or refractory hematological malignancies","volume":"108","author":"O'Connor","year":"2006","journal-title":"Blood"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2009.02.003_bib9","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V112.11.864.864","article-title":"Initial results of PX-171-003, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma (MM) [abstract]","volume":"112","author":"Jagannath","year":"2008","journal-title":"Blood"},{"issue":"11s","key":"10.1053\/j.seminhematol.2009.02.003_bib10","first-page":"320","article-title":"Initial results of PX-171-004, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed myeloma (MM)","volume":"112","author":"Vij","year":"2008","journal-title":"Blood"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2009.02.003_bib11","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1182\/blood.V112.11.2770.2770","article-title":"Phase 1 clinical trial of NPI-0052, a novel proteasome inhibitor in patients with multiple myeloma [abstract]","volume":"112","author":"Richardson","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib12","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib14","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib15","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1200\/JCO.2004.10.052","article-title":"Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma","volume":"22","author":"Schey","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1600-0609.2004.00393.x","article-title":"Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis","volume":"74","author":"Streetly","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib17","doi-asserted-by":"crossref","first-page":"866s","DOI":"10.1182\/blood.V112.11.866.866","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone (Pom\/dex) is highly effective therapy in relapsed multiple myeloma [abstract]","volume":"112","author":"Lacy","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib18","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2002-11-3514","article-title":"Molecular sequelae of histone deacetylase inhibition in human malignant B cells","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib19","doi-asserted-by":"crossref","first-page":"14374","DOI":"10.1073\/pnas.202445099","article-title":"Molecular sequelae of proteasome inhibition in human multiple myeloma cells","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib20","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1073\/pnas.2536759100","article-title":"Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications","volume":"101","author":"Mitsiades","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib21","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1158\/1078-0432.CCR-03-0561","article-title":"Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors","volume":"10","author":"Pei","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib22","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2006-04-016055","article-title":"Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells","volume":"108","author":"Catley","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000089471","article-title":"Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib","volume":"115","author":"Sutheesophon","year":"2006","journal-title":"Acta Haematol"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib24","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s10495-007-0063-y","article-title":"SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor bortezomib","volume":"12","author":"Emanuele","year":"2007","journal-title":"Apoptosis"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2006-03-013128","article-title":"NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells","volume":"110","author":"Miller","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib26","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.3748\/wjg.v13.i33.4458","article-title":"Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells","volume":"13","author":"Baradari","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib27","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1158\/0008-5472.CAN-05-2961","article-title":"Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells","volume":"66","author":"Nawrocki","year":"2006","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib28","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.bcp.2005.04.030","article-title":"HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha","volume":"70","author":"Place","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib29","first-page":"3578","article-title":"Phase I Clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously","volume":"9","author":"Kelly","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib30","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/10428190701817258","article-title":"Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma","volume":"49","author":"Richardson","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib32","doi-asserted-by":"crossref","first-page":"354A","DOI":"10.1182\/blood.V110.11.1168.1168","article-title":"Phase I trial of suberoylanilide hydroxamic acid (SAHA) plus bortezomib (Bort) in relapsed multiple myeloma (MM) patients (pts) [abstract]","volume":"110","author":"Badros","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib33","doi-asserted-by":"crossref","first-page":"355A","DOI":"10.1182\/blood.V110.11.1172.1172","article-title":"Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with bortezomib in patients with advanced multiple myeloma [abstract]","volume":"110","author":"Weber","year":"2007","journal-title":"Blood"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2009.02.003_bib34","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/blood.V112.11.871.871","article-title":"Vorinostat plus bortezomib for the treatment of relapsed\/refractory multiple myeloma: early clinical experience [abstract]","volume":"112","author":"Weber","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib35","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood-2003-01-0233","article-title":"NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma","volume":"102","author":"Catley","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib36","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1074-5521(03)00095-4","article-title":"Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays","volume":"10","author":"Haggarty","year":"2003","journal-title":"Chem Biol"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib37","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1073\/pnas.0430973100","article-title":"Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation","volume":"100","author":"Haggarty","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib38","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib39","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors","volume":"280","author":"Bali","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib40","first-page":"6763","article-title":"The phosphatidylinositol 3-kinase\/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses","volume":"60","author":"Tu","year":"2000","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib41","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1038\/sj.onc.1204833","article-title":"Biologic sequelae of interleukin-6 induced PI3-K\/Akt signaling in multiple myeloma","volume":"20","author":"Hideshima","year":"2001","journal-title":"Oncogene"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib42","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1038\/sj.onc.1205664","article-title":"Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1\/Akt signaling in human multiple myeloma cells: therapeutic implications","volume":"21","author":"Mitsiades","year":"2002","journal-title":"Oncogene"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib43","doi-asserted-by":"crossref","first-page":"359A","DOI":"10.1182\/blood.V110.11.1185.1185","article-title":"Anti-myeloma activity of selective PI-3K\/PDK\/mTOR inhibitor BEZ235 [abstract]","volume":"110","author":"McMillin","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib44","doi-asserted-by":"crossref","first-page":"200A","DOI":"10.1182\/blood.V110.11.649.649","article-title":"Anti-myeloma activity of the dual Akt\/p70(S6K) inhibitor EXEL-6075 [abstract]","volume":"110","author":"McMillin","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib45","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2141.2007.06714.x","article-title":"Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells","volume":"138","author":"Hideshima","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib46","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1182\/blood-2005-08-3434","article-title":"Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells","volume":"107","author":"Hideshima","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib47","first-page":"155","article-title":"Perifosine (KRX-0401) plus low dose dexamethasone is active in patients with relapsed and refractory multiple myeloma (MM): Perifosine MM Investigator Group phase II multicenter study update","volume":"92","author":"Richardson","year":"2007","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib48","doi-asserted-by":"crossref","first-page":"3691s","DOI":"10.1182\/blood.V112.11.3691.3691","article-title":"Phase I results of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM) [abstract]","volume":"112","author":"Jakubowiak","year":"2008","journal-title":"Blood"},{"issue":"Suppl 11","key":"10.1053\/j.seminhematol.2009.02.003_bib49","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1182\/blood.V112.11.870.870","article-title":"Phase I\/II results of a multicenter trial of perifosine (KRX-0401) + bortezomib in patients with relapsed or relapsed\/refractory multiple myeloma who were previously relapsed from or refractory to bortezomib [abstract]","volume":"112","author":"Richardson","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib50","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1016\/j.febslet.2007.05.040","article-title":"Inhibitors of the heat shock response: biology and pharmacology","volume":"581","author":"Powers","year":"2007","journal-title":"FEBS Lett"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib51","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00001622-200311000-00003","article-title":"Heat shock protein 90","volume":"15","author":"Neckers","year":"2003","journal-title":"Curr Opin Oncol"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib52","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-03-1158","article-title":"Antimyeloma activity of heat shock protein-90 inhibition","volume":"107","author":"Mitsiades","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib53","doi-asserted-by":"crossref","first-page":"660A","DOI":"10.1182\/blood.V104.11.2404.2404","article-title":"Anti-tumor activity of KOS-953, a cremophor-based formulation of the hsp90 inhibitor 17-AAG [abstract]","volume":"104","author":"Mitsiades","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib54","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1080\/10428190500472123","article-title":"Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma","volume":"47","author":"Duus","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib55","doi-asserted-by":"crossref","first-page":"17408","DOI":"10.1073\/pnas.0608372103","article-title":"Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90","volume":"103","author":"Sydor","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib56","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood-2006-05-024372","article-title":"STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival","volume":"109","author":"Chatterjee","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib57","doi-asserted-by":"crossref","first-page":"6826","DOI":"10.1158\/1078-0432.CCR-06-1331","article-title":"Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma","volume":"12","author":"Francis","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib58","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1182\/blood-2006-11-053728","article-title":"Heat shock protein inhibition is associated with activation of the unfolded protein response (UPR) pathway in myeloma plasma cells","volume":"110","author":"Davenport","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib59","doi-asserted-by":"crossref","first-page":"660A","DOI":"10.1182\/blood.V104.11.2403.2403","article-title":"IPI-504: A novel hsp90 inhibitor with in vitro and in vivo antitumor activity [abstract]","volume":"104","author":"Mitsiades","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib60","doi-asserted-by":"crossref","first-page":"109a","DOI":"10.1182\/blood.V106.11.362.362","article-title":"Phase 1 clinical trial of KOS-953+bortezomib (BZ) in relapsed refractory multiple myeloma (MM) [abstract]","volume":"106","author":"Chanan-Khan","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib61","series-title":"A multicenter phase 1 clinical trial of tanespimycin (KOS-953) + bortezomib (BZ): encouraging activity and manageable toxicity in heavily pre-treated patients with relapsed refractory multiple myeloma (MM)","author":"Richardson","year":"2006"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib62","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00280-007-0546-0","article-title":"IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells","volume":"61","author":"Patterson","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib63","doi-asserted-by":"crossref","first-page":"1022A","DOI":"10.1182\/blood.V108.11.3579.3579","article-title":"Update on phase I clinical trial of IPI-504, a novel, water-soluble Hsp90 inhibitor, in patients with relapsed\/refractory multiple myeloma (MM) [abstract]","volume":"108","author":"Siegel","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib64","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1359-6349(06)70575-4","article-title":"Overcoming resistance to tyrosine kinase inhibitors (TKIs) through inhibition of heat shock protein 90 (Hsp90) chaperone function in patients with metastatic GIST: results of a phase I trial of IPI-504, a water-soluble Hsp90 inhibitor","volume":"4","author":"Demetri","year":"2006","journal-title":"EJC Suppl"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib65","doi-asserted-by":"crossref","first-page":"719A","DOI":"10.1182\/blood.V106.11.2560.2560","article-title":"Phase I clinical trial of IPI-504, a novel, water-soluble Hsp90 inhibitor, in patients with relapsed\/refractory multiple myeloma (MM) [abstract]","volume":"106","author":"Jagannath","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib66","doi-asserted-by":"crossref","first-page":"474A","DOI":"10.1182\/blood.V110.11.1587.1587","article-title":"Activity of new heat shock protein 90 (hsp90) inhibitor NVP-AUY922 against myeloma cells sensitive and resistant to conventional agents [abstract]","volume":"110","author":"McMillin","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib67","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2008-04-151928","article-title":"SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematological tumors by abrogating signaling via Akt and ERK","volume":"113","author":"Okawa","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib68","first-page":"797A","article-title":"Lenalidomide, bortezomib, and dexamethasone (Rev\/Vel\/Dex) in patients with relapsed or relapsed\/refractory multiple myeloma (MM): preliminary results of a phase II study [abstract]","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib69","doi-asserted-by":"crossref","first-page":"92s","DOI":"10.1182\/blood.V112.11.92.92","article-title":"Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I\/II study [abstract]","volume":"112","author":"Richardson","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib70","doi-asserted-by":"crossref","first-page":"93s","DOI":"10.1182\/blood.V112.11.93.93","article-title":"Safety and efficacy of novel combination therapy with bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in newly diagnosed multiple myeloma: initial results from the phase I\/II multi-center EVOLUTION study [abstract]","volume":"112","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib71","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood.V110.11.74.74","article-title":"A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]","volume":"110","author":"Rajkumar","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.02.003_bib72","doi-asserted-by":"crossref","first-page":"94s","DOI":"10.1182\/blood.V112.11.94.94","article-title":"A phase II Study of Bortezomib (Velcade), Cyclophosphamide (Cytoxan), Thalidomide (Thalomid) and dexamethasone as first-line therapy for multiple myeloma [abstract]","volume":"112","author":"Bensinger","year":"2008","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196309000316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196309000316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:20:17Z","timestamp":1758522017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196309000316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0037196309000316"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2009.02.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2009.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}